Navigation Links
FDA Approves Luvox(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD)
Date:2/28/2008

disorders," said John H. Greist, M.D., distinguished senior scientist, Madison Institute of Medicine and clinical professor of psychiatry, University of Wisconsin Medical School. "Physicians have been using immediate-release fluvoxamine for years to treat OCD patients. Now having Once-A-Day LUVOX CR (fluvoxamine maleate) Extended-Release Capsules offers patients with SAD and OCD an additional option."

The FDA evaluated a data package involving approximately 600 patients worldwide that included three clinical trials with positive outcomes evaluating the efficacy and safety of LUVOX CR. These studies were:

Social Anxiety Disorder

-- Davidson, Jonathan, et al. Fluvoxamine-controlled release formulation

for the treatment of generalized social anxiety disorder. J Clin

Psychopharmacol 2004; 24:118-125.

-- Westenberg, Herman, et al. A double-blind, placebo-controlled study of

controlled-release fluvoxamine for the treatment of generalized social

anxiety disorder. J Clin Psychopharmacol. 2004; 24:49-55.

Obsessive Compulsive Disorder

-- Hollander, Eric, et al. A double-blind, placebo-controlled study of

the efficacy and safety of controlled-release fluvoxamine in patients

with obsessive-compulsive disorder. J Clin Psychiatry. 2003;

64:640-647.

"SAD and OCD are serious, yet treatable conditions," said Jerilyn Ross, M.A., L.I.C.S.W., president and CEO, Anxiety Disorders Association of America (ADAA). "We're excited about new treatment options -- both medications and psychological -- to help patients with these chronic and undertreated anxiety disorders. Having treatment options benefits the patient, and that's what is most important."

LUVOX CR will be available in 100 mg and 150 mg dose strengths. Over the next several weeks, Jazz Pharmaceuticals will continue to work closely with Elan on the manufacturing of LUVOX CR for commercial launch. '/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. FDA Approves NEXIUM(R) for the Treatment of Short-Term GERD in Children 1 to 11 Years Old
2. U.S. Court Approves AK Steels VEBA Health Care Settlement With Middletown Works Retirees
3. Securian Board Approves 8 Officer Promotions
4. MGT Capital Investments, Inc. Approves Share Buyback Program
5. Kaiser Permanente Approves $29 Million in Community Benefit Grants
6. Otter Tail Corporation Reports Record Revenues and Net Income From Continuing Operations for 2007; Earnings Per Share of $1.78; Board Approves Dividend Increase
7. Pennsylvania Attorney General Approves Vincentian Collaborative System-Marian Manor Integration
8. FDA Approves ASMANEX (R) TWISTHALER(R) (Mometasone Furoate Inhalation Powder) for the Once Daily Maintenance Treatment of Asthma in Children Ages 4-11
9. FDA Approves Additional Indication for Astellas MYCAMINE(R)
10. FDA Approves Labeling Change for Non-Drowsy CLARITIN(R)
11. FDA Approves Cialis(R) (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... July 01, 2015 , ... Sir Fazle Hasan Abed, BRAC’s founder ... today. Sir Fazle has been recognised for his outstanding contribution to enhancing the world's ... Quinn, President of the World Food Prize Foundation, announced this year’s winner at a ...
(Date:7/1/2015)... ... July 01, 2015 , ... The Lymphoma Research Foundation ... research and serving the lymphoma community through a comprehensive series of education programs, ... new members to their industry leading Scientific Advisory Board. LRF’s volunteer Scientific Advisory ...
(Date:7/1/2015)... Tokyo, Japan (PRWEB) , ... July 01, 2015 ... ... August 2015 of a new extraction plant for Linablue®, Spirulina-derived natural blue food ... Earthrise Nutritionals, LLC, the DIC Group’s U.S. Spirulina* production base, began in May ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... cancer enterprise of Hospital Corporation of America (HCA), as it further expands its ... announced today. , With this new partnership, OncLive’s editorial and marketing teams ...
(Date:7/1/2015)... ... July 01, 2015 , ... The 28th annual Charity Horse Show hosted by ... 2015, at 6 p.m. in Pugh Bourne Park, 343 Oakfield Road. The event will ... zoo, an Elvis impersonator, a silent auction and concessions. , Horses and riders from ...
Breaking Medicine News(10 mins):Health News:Sir Fazle Hasan Abed Receives World Food Prize 2Health News:Sir Fazle Hasan Abed Receives World Food Prize 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 2Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 4Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 5Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 2Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 3Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 2Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 3
... on gum bacteria, scientists had been able to use ... the oral cavity. ,The dental samples obtained from ... light (380 to 520nm). The light had selectively killed ... dental plaque samples obtained from patients. Medium strength light ...
... a research covering 218 diabetic patients and 799 non-diabetic ... scientists of Epidemiologic Research and Information Center, Seattle, US ... having a urinary tract infection for women who have ... annual follow up of testing for hemoglobin A1c, urine ...
... drug market watchdog Food and Drug Administration had announced a ... the class of non-steroidal anti-inflammatory drugs that are sold with ... withdrawal of the drug Bextra (valdecoxib) from Pfizer, Inc. ... as FDA had reports that the overall risk associated with ...
... pattern of rising early from bed in the mornings have ... ,The behavior is called familial advanced sleep phase syndrome ... said to be the phenotype of the gene PER2. The ... phosphorylation site in the casein kinase I (CKI) domain of ...
... Institute Maryland USA had found out a gene that is ... syndrome. ,The disease is caused by a point ... of the major genes that lead to the physiology of ... individual with the disease have severe abnormalities in the nuclear ...
... had pointed out that excessive exposure to television at the ... behavior.// ,A child is considered to be a bully ... be done by actual physical attack on others or by ... not read aloud to their children, or provide them with ...
Cached Medicine News:
(Date:7/1/2015)... SHANGHAI , July 1, 2015 Qiming ... Hu to Managing Partner effective immediately. ... He has lead and participated in many Qiming healthcare ... leaders in the Chinese market. Qiming, s success in ... and he has distinguished himself with his outstanding advocacy ...
(Date:7/1/2015)... , July 1, 2015 Lupin ... Bring Total Number of MPP Sub-licensees to Fourteen ... Patent Pool (MPP) announced the rapid expansion of its network ... than 50 projects to develop MPP-licensed antiretrovirals (ARVs). New companies ... (DTG), a promising new HIV medicine the MPP licensed from ...
(Date:7/1/2015)... Boston Scientific Corporation (NYSE: BSX ) will webcast its ... second quarter ended June 30, 2015 on Thursday, July 23, ... be hosted by Mike Mahoney , president and chief ... and chief financial officer. A live webcast of ... website. Webcast registration is available on the Investor Relations section ...
Breaking Medicine Technology:Qiming Announces the Promotion of William Hu to Managing Partner 2The Medicines Patent Pool Increases its Generic Manufacturing Network to Ramp-Up Production of Low Cost Antiretrovirals (ARVs) 2The Medicines Patent Pool Increases its Generic Manufacturing Network to Ramp-Up Production of Low Cost Antiretrovirals (ARVs) 3Boston Scientific To Webcast Second Quarter 2015 Earnings Call On July 23 2
... Reportlinker.com announces that a new market research report is available in its catalogue: , ... Market Analysis 2010-2025 , , , ... Reports details , ... in this diverse market with high, growing demand worldwide? , , , ...
... , May 4 Emdeon Inc. (NYSE: ... revenue and payment cycle management solutions, today announced a ... solutions company delivering more accurate, timely and comprehensive data ... will be able to offer its 1,200 healthcare payer ...
Cached Medicine Technology:Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 2Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 3Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 4Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 5Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 6Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 7Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 8Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 9Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 10Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 11Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 12Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 13Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 14Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 15Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 16Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 17Emdeon Announces Strategic Alliance with Enclarity to Address Industry Problems Created by Inconsistent Provider Data Quality 2Emdeon Announces Strategic Alliance with Enclarity to Address Industry Problems Created by Inconsistent Provider Data Quality 3Emdeon Announces Strategic Alliance with Enclarity to Address Industry Problems Created by Inconsistent Provider Data Quality 4Emdeon Announces Strategic Alliance with Enclarity to Address Industry Problems Created by Inconsistent Provider Data Quality 5
... infectious disease ELISA products make us a ... protocols for faster integration into the busy ... increased reliability and run-to-run consistency. Our Infectious ... for a wide range of serological assays ...
... Our breadth of infectious disease ELISA ... field. With standard assay protocols for faster ... Disease ELISA products provide increased reliability and ... includes antibody detection assays for a wide ...
... Our breadth of infectious disease ELISA ... field. With standard assay protocols for faster ... Disease ELISA products provide increased reliability and ... includes antibody detection assays for a wide ...
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
Medicine Products: